Drug profile

The FDA adverse-event record for Onsior

164 FDA reports name Onsior, a high-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#598 of 2,679
by report volume (all drugs)
164
adverse-event reports
25.6%
death-coded share
Cat
most-reported species

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Onsior ranks #597 of 2679 by total reports (164) and #162 of 1130 by death-coded share (25.6%). National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#597
This drug, reports of 2679
#162
This drug, death share of 1130

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Onsior has 164 reports now versus 164 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
−0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Onsior changes

Signature read: death-coded report count at 42 is the most distinctive stamp on Onsior's FDA AER row.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
164
Total Reports
42
Deaths Reported
25.6%
Death-coded share of reports

Active Ingredients

Onsior

Administration Routes

UnknownOralSubcutaneousIntravenous

Species Affected

Cat 160
Dog 4

Most Affected Breeds

Domestic Shorthair 87
Cat (unknown) 22
Domestic Longhair 13
Cat (other) 10
Siamese 6
Domestic Mediumhair 6
Himalayan 5
Russian 2
Ragdoll 2
Dachshund (unspecified) 2

Most Reported Reactions

Lethargy (see also Central nervous system depression in Neurological) 28
Death by euthanasia 25
Not eating 24
Fever 20
Ataxia 18
Weight loss 17
Death 17
Leucocytosis NOS 13
Not drinking 13
Vomiting 13
Vocalisation 12
Dilated pupils 12

Outcome Breakdown

Ongoing
96 (58.5%)
Euthanized
25 (15.2%)
Died
17 (10.4%)
Outcome Unknown
15 (9.1%)
Recovered/Normal
10 (6.1%)
Recovered with Sequela
1 (0.6%)

Onsior: high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

High-volume nationwide drug peers

Two openFDA-derived peer sets for Onsior, both floored at ≥50 reports so the neighborhoods stay in the advertised mass.

Similar death-coded share

Nearest other drugs by death-coded share (25.6% here), distinct from the volume row.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Onsior (#598 of 2,679 by report volume); death-coded 25.6%. PlainBreed drug row · death-coded report count stamp 42 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →